促肝细胞生长素联合恩替卡韦治疗对慢性重型肝炎血清学指标及病情转归的影响

Effect of hepatocyte growth-promoting factor combined with entecavir therapy on serological indicators and outcome of chronic severe hepatitis

目的:分析促肝细胞生长素联合恩替卡韦治疗对慢性重型肝炎血清学指标及病情转归的影响。方法:将在本院和深圳市第三人民医院治疗的慢性重型肝炎患者110例纳入研究,根据治疗方式不同分为接受常规抗病毒治疗的对照组52例,接受抗病毒药物联合促肝细胞生长素治疗的观察组58例。对比两组炎症相关指标,血清生化指标,IL-10、IL-12、IFN-γ及HBV DNA含量,COX-2代谢产物表达水平差异。结果:观察组接受治疗后血清WBC、PMN、CRP、内毒素、PCT水平明显低于对照组(P<0.05);观察组接受治疗后血清TBIL、AFP、BUN、Cr水平低于对照组,A、CHE水平高于对照组(P<0.05);观察组治疗后血清IL-10、IL-12、IFN-γ及HBV DNA含量低于对照组(P<0.05);观察组治疗后血清TXB2、T/6-K水平低于对照组,6-keto-PGF1α水平高于对照组(P<0.05)。结论:慢性重型肝炎患者接受抗病毒药物联合促肝细胞生长素治疗,可以有效改善肝功能并抑制乙肝病毒复制活性,在缓解病情及提高预后方面均有积极意义。

Objective.. To analyze the effect of hepatocyte growth-promoting factor combined with entecavir therapy on serological indieators and outcome of chronic severe hepatitis. Methods： A total of 110 patients with chronic severe hepatitis who were treated in our hospital and the Third People＇s Hospital of Shenzhen were enrolled for study and divided into control group with 52 eases who received conventional antiviral therapy and observation group with 58 cases who received antiviral drug combined with hepatocyte growth-promoting factor therapy. Differences in inflammation related indicators, serum biochemical indicators, interleukin （IL）-10, IL-12, interferon-7 and HBV DNA contents as well as COX-2 metabolite expression levels be- tween two groups were compared. Results; Serum white blood cell, PMN, C-reactive protein, endotoxin and PCT levels in ob-servation group after treatment were significantly lower than those in control group （P〈0.05） serum total bilirubin, alpha fetal protein, blood urea nitrogen and creatinine levels in observation group after treatment were lower than those in control group, while levels of albumin and cholinesterase were higher than those in control group （P〈0.05） ; serum IL-10, IL 12, in- terferon-γ and HBV DNA contents in observation group after treatment were lower than those in control group （P〈0.05） ; se- rum thromboxaneB2 and ratio of thromboxaneB2/6-keto-prostaglandin1α levels in observation group after treatment were lower than those in control group, while 6-keto prostaglandin1α level was higher than that in control group （P〈0.05）. Conclusions： Antiviral drugs combined with hepatoeyte growth-promoting factor therapy for patients with chronic severe hepatitis can effectively improve liver function and inhibit the activity of hepatitis B virus replication, with an active significance in both relieving the disease and improving the prognosis.